Investigators assessed whether intravesical BCG is necessary for patients with high-grade T1 nonmuscle-invasive bladder cancer who have unremarkable histology on the second transurethral resection.

On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024Expect to report interim 12-month data in ADVANCED-2 trial of TARA-002 in NMIBC in ...

Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that U.S.

CG Oncology (CGON) announced the publication in Nature Medicine of Phase 1b investigator-sponsored study results evaluating intravesical cretostimogene grenadenorepvec in combination with Bristol ...

UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will ...

The patents are for salmonella-based approaches to enhance the efficacy of immune checkpoint inhibitors and elicit immune ...

Patients were further queried to identify those who received adequate BCG induction (defined as ≥ 5 weekly instillations). They then summarized the distribution of this group and the treatments ...

This study included a review of consecutive patients diagnosed with NMIBC between January 2005 and May 2023 to identify ...

The FDA approved zolbetuximab (Vyloy) on October 18, 2024, as a first-line treatment for locally advanced unresectable or ...

The FDA is currently evaluating the application of intravesical mitomycin for low-grade intermediate-risk non–muscle-invasive bladder cancer.